Logo

UCB Reports Interim Results of Bimekizumab in P-III BE OPTIMAL Study for the Treatment of Active Psoriatic Arthritis

Share this
UCB Reports Interim Results of Bimekizumab in P-III BE OPTIMAL Study for the Treatment of Active Psoriatic Arthritis

UCB Reports Interim Results of Bimekizumab in P-III BE OPTIMAL Study for the Treatment of Active Psoriatic Arthritis

Shots:

  • The P-III BE OPTIMAL study evaluates bimekizumab vs PBO in 852 patients with active PsA who are biologic disease-modifying anti-rheumatic drug naïve
  • The trial met its 1EPs & 2EPs  i.e., patients treated with bimekizumab achieved an improvement in signs & symptoms of the disease from baseline as measured by ACR 50 response (50% vs 20%) @16wks., improvements in physical function as measured by HAQ-DI; skin clearance as measured by 90% improvement in PASI 90; joint radiographic progression as measured by vdHmTSS @16wks.
  • The safety profile was consistent with previous studies & no new safety signals were observed. The therapy is currently under US FDA’s review to treat PsO

Ref: PRNewswire | Image: UCB


Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions